Inclusion Criteria:

- Give written informed consent prior to study, with understanding that the patient has
the right to withdraw from the study at any time without prejudice

- Be female of male and ≥18 and ≤75 years of age

- Be ambulatory and have ECOG performance status of ≤1

- Have histological confirmed sarcoma

- Locally advanced or metastatic sarcoma who receive first-line chemotherapy.

- Have at least one target lesion according to the RECIST criteria.

Exclusion Criteria:

- Pregnant or lactating women

- patient has received chemotherapy drugs including gemcitabine,vincristine and
cisplatin

- Chemotherapy within four weeks preceding treatment start

- ECOG ≥ 2

- Radiotherapy to the axial skeleton within the 4 weeks preceding study treatment start
or insufficient recovery from the effects of prior radiotherapy

- Participation in any investigational drug study within 4 weeks preceding treatment
start

- History of another malignancy within the last five years except cured basal cell
carcinoma of skin and carcinoma in-situ of uterine cervix .Abnormal laboratory
values: hemoglobin < 8. 0g/dl, neutrophil< 1.5×109/L, platelet< 100×109/L.

- serum creatine > upper limit of normal (ULN)

- serum bilirubin > ULN

- alanine aminotransferase(ALT) and aspartate aminotransferase(AST)>5×ULN

- alkaline phosphatase(AKP)>5×ULN

- Serious uncontrolled intercurrence infection

- Life expectancy of less than 3 months